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Abstract: Gene therapy for gastric cancer and gastric ulcer is a rationalized strategy since various 
genes correlate with these diseases. Since gene expressions in non-target tissues/cells cause side 
effects, a selective gene delivery system targeted to the stomach and/or cancer must be developed. 
The route of vector transfer (direct injection, systemic, intraperitoneal, gastric serosal surface and 
oral administration) is an important issue which can determine efficacy and safety. Strategies for 
cancer gene therapy can be categorized as suicide gene therapy, growth inhibition and apoptosis 
induction, immunotherapy, anti-angiogenesis, and others. Combination of the target gene with 
other genes and/or strategies such as chemotherapy and virotherapy is promising. Candidates for 
treatment of gastric ulcer are vascular endothelial growth factor, angiopoietin-1, serum response 
factor, and cationic host defense peptide cathelicidin. In this review, we discuss stomach- and 
cancer-targeted gene transfer methods and summarize gene therapy trials for gastric cancer and 
gastric ulcer. 
 




The stomach is a digestive organ that is essential for nutrient intake. An acidic 
environment in the stomach is required for the digestive system and a barrier function against 
acidic pH is necessary. Alcohol, drugs, stress, and Helicobacter pylori (H. pylori) reduce barrier 
function and cause gastritis and gastric ulcer. Moreover, gastric cancer is one of the most common 
malignant tumors in the world. It was the second most common cause of death from cancer 
(700,000 deaths annually) after lung cancer in 2002, according to the International Agency for 
Research on Cancer [1]. In 2002, the incidence of gastric cancer was estimated to be 934,000 new 
cases per year worldwide [1]. The mortality due to Japanese gastric cancer was over 50,000 
deaths annually in 2005 according to the Center for Cancer Control and Information Services, 
National Cancer Center, Japan. Surgical resection of gastric cancer without metastasis is a 
first-line therapy and provides relatively good prognosis compared to other cancers. However, 
recurrence, liver metastasis and/or peritoneal dissemination in gastric cancer are serious problems 
with high mortality. Advanced gastric cancer does not generally respond to conventional 
chemotherapy or radiotherapy [2].  
To treat gastric cancer and gastric ulcer, gene therapy is a promising approach because 
mutation, overexpression and insufficient expression of various genes correlate with these 
diseases. Gene delivery systems in vivo can be categorized as viral [3-5] and non-viral [6-8] 
approaches. Although the viral vectors have not yet proved to be a safe gene delivery method [9, 
10], the transfection efficiency of viral vectors is generally much higher than that of non-viral 
vectors. Not only transgene expression, but also down-regulation of internal genes, is possible 
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using antisense oligodeoxyribonucleotides [11] and siRNA [12, 13]. Selection of administration 
routes for gene therapy is an important issue, along with vector and target gene selection. In this 
review, we discuss stomach-targeted gene transfer methods and summarize gene therapy trials for 
gastric cancer and gastric ulcer. 
 
SELECTIVE DELIVERY OF GENES TO THE STOMACH OR GASTRIC CANCER 
Since it is thought that gene transfer to non-target organs/cells can result in severe 
adverse effects, selective gene transfer to target organ/cells, i.e. the stomach or cancer, is a major 
challenge in gene therapy, and a gene delivery system targeted to the stomach or cancer should be 
developed. The administration route is an important factor since it can greatly affect 
biodistribution of vectors. Active targeting to cancer cells has also been tried by several groups. 
More than half of advanced gastric cancers overexpress the carcinoembryonic antigen (CEA) 
protein [2, 14]. CEA is an attractive target since its expression in normal cells is generally low. 
Khare et al. developed a murine leukemia virus-based recombinant retroviral vector that displays 
a chimeric envelope protein containing a single-chain variable fragmented antibody to CEA [15]. 
Normally, wild-type ecotropic viruses do not infect human cells. In contrast, this vector infected 
human CEA-expressing cells. Tanaka et al. constructed a genetically modified adenovirus 
incorporating an IgG Fc-binding motif from the Staphylococcus protein A, Z33, within the HI 
loop (Adv-FZ33) [16]. Combination of Adv-FZ33 with an anti-CEA monoclonal antibody 
resulted in 20 times higher LacZ or EGFP gene expression than that with a control antibody in 
MKN-45 gastric cancer cell line. Notably, this system is easily applicable to other antibodies. 
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Epithelial cell adhesion molecule (EpCAM) is another target for tumor-selective gene transfer. 
Heideman et al. reported that EpCAM-targeted adenoviral vector using bispecific antibodies 
against the adenovirus fiber-knob protein and EpCAM selectively infected gastric and esophageal 
cancer cell lines [17]. 
On the other hand, a cancer-specific promoter is another tool achieving cancer-specific 
gene expression. A CEA promoter is commonly used for this purpose [18-20]. However, the gene 
expression level of tumor-specific promoters such as CEA promoter is generally low. To resolve 
this problem, Ueda et al. designed a Cre/loxP system under the control of a CEA promoter, and 
gene expression (under the control of a strong promoter) was markedly enhanced while 
maintaining specificity using the Cre/loxP regulation system [21]. Cyclooxygenase-2 (COX-2) 
promoter is also an attractive promoter since its activity is high in gastrointestinal cancer (or 
inflammation site) while its activity in most tissues such as the liver is low [22-24]. Yamamoto et 
al. demonstrated that COX-2 promoter was less active than cytomegarovirus (CMV) promoter in 
the liver, lung and kidney after tail vein injection of adenoviral vector, whereas activity of COX-2 
promoter in subcutaneous tumors of gastric cancer cells after intratumoral injection was similar 
level with that of CMV promoter [25]. 
 
ROUTES OF VECTOR TRANSFER 
Routes of vector transfer into the stomach (summarized in Fig. (1) and Table 1) can 
theoretically determine the efficacy and safety of vectors. When foreign genes are administered 
via the vasculature route, they are distributed to the whole body through the bloodstream, leading 
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to inadequate stomach-selective or disease site-selective gene delivery. Injection of vectors into 
the gastric artery may resolve this problem; however, there are no reports about stomach-selective 
gene transfer via the gastric artery. As for tumors, there are considerable numbers of reports about 
cancer-targeted delivery systems via the vasculature route. One such system is the PEGylated 
carrier system [26]. PEGylated carriers accumulate in the tumor via an enhanced permeability and 
retention (EPR) effect [27]. Active targeting systems utilizing tumor-specific surface receptors 
have also been developed [28-30]. However, no researchers have achieved stomach- or gastric 
cancer-selective gene transfer via the systemic circulation. Thus, it may be necessary to select 
other routes for stomach-targeted gene therapy. 
 
Direct injection to the stomach 
When plasmid DNA is injected directly into muscle, efficient transfection activity can be 
obtained without any carriers [31]. This method has been applied to the liver [32], heart [33], 
spleen [34], tumor [35], and also to the stomach [36]. However, multiple injections are necessary 
for gene transfer to a large population of gastric cells. Moreover, there is great concern about 
safety because this method requires physical force against the organs; consequently, repeated 
administration of plasmid DNA is limited, except for solid tumors. 
 
Serosal route 
The prognosis of gastric cancer patients with serosal invasion is poor [37]. The survival 
rate is also influenced by peritoneal dissemination [38]. Therefore, the serosal route of gene 
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transfer is attractive to treat serosal invasion and peritoneal dissemination of gastric cancer. 
Intraperitoneal injection has been widely applied as a gene transfer route [20, 39, 40]. Since 
intraperitoneal injection of vectors can result in non-specific gene transfer into non-target 
sites/cells in the peritoneal cavity, an active targeting system and/or cancer-specific promoter is 
required for safety. 
The stomach-selective gene transfection method is expected to be a safe and effective 
treatment against gastric cancer localized in the stomach. We have developed an organ-selective 
gene transfer method, instilling naked plasmid DNA onto the mesothelial surface of target organs 
including the liver [41], unilateral kidney [42], spleen [43], unilateral lung [44], and stomach [45, 
46] in mice. Although frequent dosing using this method is limited due to necessity of 
laparoscopy, application of an implantable infusion pump will prolong duration of gene 
expression. Gastric serosal surface instillation of plasmid DNA encoding an anti-cancer gene is 
thought to act primarily against the invasion of gastric cancer to the serosal side, although it may 
be difficult for plasmid DNA to penetrate into the mucosal side. However, prophylactic gastric 
serosal instillation of plasmid DNA combined with the resection of mucosal cancer might be 
useful to prevent invasion of the remaining cancer cells. Furthermore, we previously reported that 
gastric serosal surface application of the anti-cancer drug 5-fluorouracil (5-FU) resulted in 
comparable distribution of 5-FU between the mucosal and serosal sides in rats; consequently, 
5-FU was efficiently distributed to the mucosal side from the serosal side prior to distribution to 
the systemic circulation [47]. Simultaneous administration of gene medicine and anti-cancer 




The oral route is the most attractive and challenging route. Non-invasive administration 
is possible by the oral route. Potential daily intake is also one of the merits of oral administration 
of vectors. Moreover, since gastric cancer and gastric ulcer are firstly generated on the mucosal 
side of the stomach, vectors can act against these diseases effectively. However, the epithelial 
barrier, low pH and digestive fluid are major obstacles for gene transfer. Shao et al. reported that 
the in vivo stability of a recombinant adeno-associated virus type 2 vector could be improved by 
gastric acid neutralization with sodium bicarbonate and protease inhibition with aprotinin [48]. 
Despite these changes, transduction after oral administration of this vector remained low. (Shao et 
al. did not find β-galactosidase-positive cells in any of the mice.) We also failed to detect 
transgene expression after intragastric injection of plasmid DNA in mice [46]. To overcome these 
obstacles, microparticles and nanoparticles are a promising approach. Chitosan-DNA 
microparticles could protect the encapsulated plasmid DNA from nuclease degradation [49]. In in 
vivo-animal studies, a blue color was observed with X-gal staining of histological stomach and 
small intestine sections after oral administration of chitosan-DNA microparticles. More recently, 
Zheng et al. reported that chitosan nanoparticles using quaternized chitosan (60% trimethylated 
chitosan) which were given via a gastric feeding tube exhibited green fluorescent protein 
expression in the mucosa of the stomach, duodenum, jejunum, ileum, and large intestine [50]. 
Furthermore, Bhavsar and Amiji developed a hybrid system dubbed the 
nanoparticles-in-microsphere oral system (NiMOS) which consists of gelatin nanoparticles 
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(containing plasmid DNA) and a poly(epsilon-caprolactone) outer shell [51]. NiMOS resided in 
the stomach and small intestine for relatively longer than gelatin nanoparticles alone. Future 
application of these systems to viral vectors may improve transduction efficiency. It may be 
difficult for an oral delivery system alone to achieve stomach-selective gene transfer; therefore, 
combination with an active targeting system and/or cancer-specific promoter will be required. 
Gene transfer via these routes may result in gene expression in a limited region, i.e., 
administration site (mucosal or serosal sides for the oral or serosal route, or the submucosal and 
muscular layers for direct injection). Combination of these routes can theoretically resolve this 
problem. 
 
APPROACHES TO TREAT GASTRIC CANCER  
Several approaches to treat gastric cancer have been reported. These can be categorized 
as suicide gene therapy, growth inhibition and apoptosis induction, immunotherapy, 
anti-angiogenesis, and others (Table 2). Since the efficacy of single gene transfer is generally low, 
combination of several strategies should be considered. 
 
Suicide gene therapy 
The narrow therapeutic range of anti-cancer drugs is major problem of chemotherapy; 
frequently, effective and toxic doses are inverted. To improve the efficacy of anti-cancer drugs, 
suicide gene therapy is a promising approach [52]. Suicide gene therapy is defined as a 
combination of a suicide gene with a less-toxic prodrug, such as herpes simplex virus thymidine 
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kinase (HSVtk) with ganciclovir (GCV) and Escherichia coli cytosine deaminase (CD) with 
5-fluorocytosine (5-FC). If a suicide gene is selectively transferred to the tumor cells, the 
systemically administered prodrug can be converted to its active form in tumor cells. Moreover, 
suicide gene therapy is effective even with small populations of suicide gene-positive cells 
because the active form of the prodrug can spread from a suicide gene-positive cell to 
neighboring cells via gap junctions. This effect is known as the “bystander effect”, which was 
originally described as a phenomenon that HSVtk-positive cells sensitive to GCV were toxic to 
nearby tumor cells resistant to GCV. [53]. Tanaka et al. tested a recombinant adenovirus vector 
carrying the HSVtk gene coupled to the CEA promoter for human gastric carcinoma cells in vitro 
[18]. The 50% growth inhibitory concentrations (IC50) of GCV were 21 and 5.8 μM for 
CEA-producing gastric carcinoma cell lines MKN28 and MKN45, while IC50 in a 
CEA-non-producing cancer cell line MKN1 was 320 μM. This system, i.e. a suicide gene under 
the control of a cancer-specific promoter, is also effective in vivo. Tanaka et al. continuously 
tested the in vivo effect of the same system, and intratumoral injection of the vector with 
intraperitoneal injection of GCV inhibited the growth of subcutaneous tumor xenografts of gastric 
cancer by 20% compared to untreated tumors [19]. Lan et al. reported that intraperitoneal 
injection of an adenovirus carrying the CD gene under the control of a CEA promoter with 5-FC 
suppressed tumor growth and prolonged survival of mice in MKN45 tumor xenograft model, 
suggesting this system is also effective against peritoneal dissemination [20]. In contrast, 
significant hepatic toxicity was noted in animals treated with an adenovirus carrying the CD gene 
under the control of a non-specific strong promoter (CAG promoter), suggesting that selective 
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gene transfer is an important issue. 
 
Growth inhibition and apoptosis induction 
Since abnormal gene expression and/or mutation of various oncogenes and 
tumor-suppressor genes correlate to proliferation and survival of tumor cells, gene therapy is 
rational. Suppression of oncogenes and/or correction of function of tumor-suppressor genes can 
inhibit tumor growth and induce apoptosis of tumor cells. Apoptotic signaling pathways are 
summarized in Fig. (2). 
The functional loss of the tumor-suppressor p53 gene, the guardian of the genome, is the 
most common event in carcinogenesis [54]. p53 participates in several pathways of the cell cycle, 
including activation of genes that inhibit cell cycle progression into the S phase, promotion of 
DNA repair, and induction of apoptosis [55]. Point mutations of the p53 gene have been reported 
in more than 60% of gastric cancer cases and this leads to genetic instability and uncontrolled cell 
proliferation [56]. Restoration of p53 function has been shown to stabilize the malignant 
phenotype of neoplastic cells [57, 58]. Overexpression of wild-type p53 induces growth arrest 
and/or apoptosis of p53-mutated gastric cancer cells in vitro [59]. Moreover, Ohashi et al. 
reported that p53-specific growth inhibition after transduction with adenoviruses encoding 
wild-type p53 was observed in vitro in two (MKN1 and MKN7) of four gastric cancer cell lines 
with mutated p53, but not in a wild-type p53 cell line (MKN45) [60]. The mechanism of gastric 
cancer cell death was found to be apoptosis. In this report, in vivo studies showed that the growth 
of subcutaneous tumors of p53 mutant MKN1 cells was inhibited by direct injection of an 
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adenovirus, while no growth inhibition was observed in p53 wild-type MKN45 tumors. p51 
(p73L/p63/p40/KET), a p53 homologue [61, 62], is another candidate of cancer gene therapy. p51 
binds to p53-responsive elements to up-regulate some p53 target genes and has been suggested to 
share partially overlapping functions with p53 [63-65]. Kunisaki et al. tested the 
growth-suppressive effects of adenoviral transfer of p51A in several cancer cells including gastric 
cancer in vitro, and observed a significant anti-tumor effect on day 6 in all kinds of tumors 
analyzed irrespective of the expression level of endogenous p51 [66]. 
Cancer cells expressing wild-type p53 are relatively resistant to gene transfer of p53 [67] 
including gastric cancer cells [60]. Activation of p53 leads to G1 arrest through induction of p21 
expression, or apoptosis by activation of bax expression; however, the latter does not occur in all 
cells [55]. Therefore, direct induction of apoptosis by proapoptotic gene transfer is rational. Bax is 
a strong proapoptotic gene that causes cytochrome c release from mitochondria and subsequently 
activates the caspase pathway leading to apoptosis [68, 69]. It was demonstrated that 
adenovirus-mediated bax gene transfer could effectively suppress tumor growth in both 
p53-sensitive and p53-resistant human lung carcinoma cell lines [70]. As for a gastric cancer 
model, Tsunemitsu et al. reported that adenoviral bax treatment was more effective in suppressing 
both subcutaneous and peritoneally disseminated MKN-45 tumors than p53 treatment [71]. On 
the other hand, down-regulation of anti-apoptotic genes is also an important strategy. 
Overexpression of the anti-apoptotic protein bcl-2 has been associated with drug resistance in 
various human malignancies; the expression of bcl-2 was down-regulated in chemotherapy 
responders, whereas its expression was increased or unchanged in non-responders [72, 73]. The 
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introduction of the bcl-2 gene in vitro was followed by decreased drug sensitivity in tumor cells 
[74, 75]. These findings suggest that bcl-2 affects responsiveness to chemotherapy in tumor cells. 
Overexpression of bcl-2 was confirmed in gastric carcinoma [76]. Kim et al. reported that 
down-regulation of bcl-2 by antisense bcl-2 enhanced the anti-tumor effect of cisplatin (CDDP) 
and paclitaxel in MKN45 gastric carcinoma xenografts in vivo [77]. In contrast, silencing bcl-XL, 
a bcl-2 family anti-apoptotic protein, by siRNA increased spontaneous apoptosis without 
simultaneous drug treatment in MGC-803 gastric carcinoma cells in vitro [78]. 
Rho family proteins, members of the Ras superfamily of small GTPases, have been 
shown to regulate several signal transduction pathways, and are involved in a variety of biological 
processes such as cell morphology [79, 80], motility [81], proliferation [82], and apoptosis [83]. 
Several reports have shown that RhoA expression is up-regulated in cancers, including gastric 
cancer [84]. Interleukin-6 (IL-6) can promote AGS gastric carcinoma cell motility and 
invasiveness via activation of the c-Src/RhoA/ROCK signaling pathway; thus, high expression of 
RhoA in gastric cancer cells is highly correlated with aggressive lymph node metastasis, more 
advanced tumor stage, histologically diffuse type and poor survival [85]. Liu et al. reported that 
inhibition of RhoA by RhoA-specific siRNA or dominant-negative RhoA expressions reversed 
the malignant phenotype of gastric cancer cells in vitro [86]. Sun et al. demonstrated that a 
combination of RhoA and RhoC siRNA-expressing adenoviral transfer could inhibit the 
proliferation and invasiveness activity of gastric carcinoma SGC7901 cells [87]. 
The Fas ligand (FasL), a member of the tumor necrosis factor family, initiates apoptosis 
by binding to its surface receptor Fas (CD95) and subsequent activation of caspase cascades [88]. 
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Gastric carcinoma SGC-7901 cells infected with adenovirus encoding FasL resulted in decreased 
cell growth and colony-forming activity in vitro and in vivo tumor xenografts (intratumoral 
injection) [89]. Pro-caspase-8 is a downstream molecule of Fas and is activated by FasL-Fas 
binding [90]. Activated caspase-8 can activate executioner caspases such as caspase-3 [91]; 
therefore, caspase-8 is attractive as a gene transfer candidate. However, overexpression of 
caspase-8 can result in self-oligomerization and subsequent activation in the absence of any 
apoptotic signal [92], which leads to non-specific cell death. Nishimura et al. designed an 
adenovirus encoding pro-caspase-8 for induction of anoikis, a kind of apoptosis in detached cells 
[93]. This system would act selectively against detached cells such as peritoneal dissemination of 
gastric carcinoma cells. In fact, they successfully demonstrated selective suppression of peritoneal 
dissemination with this system, while there were no distinct effects on cell viability or growth 
either of attached MKN45 cells or s.c. tumor growth in SCID mice. Gene transfer of the active 
form of executioner caspase-3 might more directly induce apoptosis of cancer cells. Srinivasula et 
al. generated constitutively active caspase-3 by switching the order of its two subunits (and 
combining them with a linker) [94]. This reversed-caspase-3 (rev-caspase-3) was applied to 
gastric cancer cells and the growth of SGC7901 cells was suppressed in a time-dependent manner 
[95]. 
Nuclear factor-kappa B (NF-κB) is a family of stimulus-induced transcription factors 
that plays important roles in developmental and immune response [96, 97]. The NF-κB pathway 
also has a role in tumor initiation, survival, and progression [98-101]. Tumor necrosis factor 
(TNF), a major mediator of apoptosis, also induces cell survival signals such as activation of 
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NF-κB [102]. Blocking NF-κB activation by inhibiting the activity of the proteasome enhanced 
TNF-α-induced apoptosis in gastric cancer cell line [103]. On the other hand, Smad7 is an 
inhibitory Smad, blocking TGF-β-induced Smad activation, terminating the signaling pathway by 
feedback regulation [104]. In addition, Smad7 has other TGF-β-independent functions, as well as 
TGF-β-dependent functions. One of the TGF-β-independent functions of Smad7 is inhibition of 
NF-κB activation [105, 106]. More recently, Hong et al. demonstrated that liposome-mediated 
transfection of Smad7 could overcome the TNF resistance in gastric cancer cells by inhibiting 
NF-κB activation [107]. 
The phosphatase and tensin homolog gene (PTEN), a tumor suppressor gene, is often 
mutated in various cancer cells [108]. Wild-type PTEN dephosphorylates the lipid second 
messenger phosphatidylinositol 3,4,5-triphosphate generated by phosphatidylinositol 3-kinase 
(PI3K) [109]. This function of PTEN negatively regulates PI3K/PKB/Akt-dependent cell survival, 
proliferation and migration [110, 111]. Although both mutation and deletion of PTEN in gastric 
cancer account for few cases [112], adenovirus-mediated transfer of PTEN can suppress tumor 
growth in in vitro gastric cancer cells and in vivo tumor xenografts [113], suggesting that 
overexpression of PTEN may be effective for growth inhibition of gastric cancer cells which 
express wild-type PTEN. 
Recently, it was reported that the tumor suppressor Fhit was a repressor of β-catenin 
transcriptional activity [114]. Clements et al. reported that β-catenin nuclear localization occurred 
in approximately 33% of gastric tumors and that β-catenin mutations occur in both diffuse- and 
intestinal-type gastric cancers [115]. Dumon et al. inhibited forestomach tumor development by 
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oral gene transfer using adenoviral or adenoassociated viral vectors expressing the Fhit gene in 
Fhit-deficient mice [116]. The same group also found that reduced bcl-2, increased bax 
expression, and increased TUNEL-positive apoptotic nuclei characterized the restored epithelia of 
the Fhit-transduced forestomach [117]. On the other hand, Dvory-Sobol et al. constructed a 
recombinant adenoviral vector that carried a lethal gene (p53 up-regulated modulator of apoptosis, 
Puma) under the control of a β-catenin/T-cell factor (Tcf)-responsive promoter [118]. This vector 
inhibited cell growth in AGS gastric cancer cells that possessed an active β-catenin/Tcf pathway. 
Survivin is expressed in mitosis in a cell cycle-dependent fashion [119]. It is potentially 
involved in both the inhibition of apoptosis and control of cell division [120, 121]. Tu et al. 
demonstrated that suppression of survivin expression in gastric cancer cells by stable transfection 
of an antisense-expressing plasmid or a dominant-negative mutant of survivin could inhibit in 
vivo tumorigenesis and angiogenesis after inoculation of these cells [122]. 
 
Immunotherapy 
In cancer patients, immune responses against cancer cells are generally insufficient. To 
enhance anti-cancer immunity, gene transfer of cytokine gene(s) has been investigated [123, 124]. 
As for gastric cancer, it was reported that the tumorigenicity of gastric carcinoma cells engineered 
to produce IL-2 was reduced in SCID mice reconstituted with peripheral blood cells from cancer 
patients, while IL-6 had no such effect [125]. On the other hand, Tanaka et al. demonstrated that 
intraperitoneal IL-10 gene transfer to the peritoneal mesothelium using an adenoviral vector 
suppressed peritoneal dissemination of MKN45 gastric cancer cells [126]. However, IL-10 is an 
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immunosuppressive cytokine [127, 128]. In fact, Sakamoto et al. reported that the prognosis of 
patients with gastric cancer expressing IL-10 was significantly worse than those without IL-10 
expression [129]. In addition, Lundin et al. showed that the peripheral blood T-cell response to H. 
pylori in gastric adenocarcinoma patients is characterized by decreased proliferation of CD8+ T 
cells and IFN-γ production by CD4+ T cells, and markedly increased production of IL-10 by cells 
both from the peripheral blood and gastric mucosa [130]. Therefore, further studies may be 
required on the usage of IL-10 prior to future clinical trials.  
A DNA vaccine has the potential to induce specific, effective and persisting immunity 
against cancer [131]. A heterologous prime-boost strategy for effective generation of cellular 
immunity consists of priming the immune system by a first vector and selective boosting this 
immunity by a second and distinct vector [132]. Lin et al. developed a heterologous prime-boost 
regime using a first oral DNA vaccine (attenuated Salmonella typhimurium containing plasmid 
DNA) and a second adenoviral vaccine combined with a gastric cancer-specific tumor associated 
antigen MG7-Ag mimotope [133]. They successfully enhanced immune response against gastric 
cancer compared to a homologous prime-boost regime using an oral DNA vaccine or adenoviral 
vaccine alone. 
Intercellular adhesion molecule (ICAM)-1 served as the counter-receptor for leukocyte 
function-associated antigen (LFA)-1 [134]. The ICAM-1/LFA-1 interaction is critical to the 
binding between effector cells and cancer cells, and ICAM-1 is a costimulatory molecule for 
immune activation [135]. Sunami et al. reported that transfection of the ICAM-1 gene inhibited 
lymph node metastasis of gastric cancer [136]. The same group also reported that gastric cancer 
-18- 
cells overexpressing ICAM-1 have a tendency to cause regression of peritoneal dissemination 
[137]. In addition, ICAM-2, second ligand for LFA-1, has structural and functional homology to 
ICAM-1 [138]. Tanaka et al. demonstrated that intratumoral injection of adenoviral ICAM-2 
inhibited the growth of s.c. gastric tumors, and also that mice with peritoneal metastasis survived 
for a longer time after adenoviral ICAM-2 transfer than controls [139]. 
 
Anti-angiogenesis 
Angiogenesis is required for invasive tumor growth and metastasis because avascular 
tumors are severely restricted in their growth potential due to the lack of a blood supply. [140]. 
Various factors such as vascular endothelial growth factor (VEGF) and angiopoietin induce 
neovascularization in tumors [141]. A soluble form of the VEGF receptor (sFlt-1) reduces the 
effects of VEGF by trapping VEGF with high affinity [142]. Sako et al. demonstrated that a 
single intraperitoneal injection of an adenoviral vector encoding sFlt-1 prevented peritoneal 
dissemination of gastric cancer cells [39]. Hepatocyte growth factor (HGF) antagonist NK4 
inhibits not only HGF receptor c-Met-mediated tumor growth, invasion and metastasis, but also 
the angiogenic responses induced by basic fibroblast growth factor, VEGF, and HGF [143, 144]. 
Two groups reported that adenoviral-mediated transfer of NK4 could suppress the tumor growth, 
invasion, angiogenesis [145], and peritoneal metastasis [40] of gastric cancer.  
Angiostatin and endostatin are potent angiogenesis inhibitors. Angiostatin is a fragment 
of plasminogen [146]. Liposome-mediated transfection of the angiostatin gene in gastric cancer 
cells inhibited tumorigenesis in nude mice [147]. Endostatin is a fragment of collagen XVIII 
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produced by hemangioendothelioma [148]. Zhang et al. constructed a gene therapy-virotherapy 
hybrid system CNHK300-mE, a replication-selective and transgene-expressing adenovirus 
carrying the mouse endostatin gene [149]. They demonstrated that the level of endostatin secreted 
from gastric cancer cells infected with CNHK300-mE was higher than those infected with a 
non-replicative adenovirus Ad-mE in vitro and in vivo. Furthermore, CNHK300-mE exhibited 
superior suppression of s.c. gastric cancer xenografts compared to CNHK300 and Ad-mE. 
Hypoxia-inducible factor (HIF), a transcription factor, is an important upstream mediator 
of VEGF expression in cancer cells [150, 151]. Stoeltzing et al. demonstrated that gastric cancer 
cells which were stably transfected with a dominant-negative form of HIF-1α secreted less VEGF 
than a control [152]. In an s.c. tumor model, they also showed tumor growth and angiogenesis 
were suppressed. Therefore, HIF may be an attractive therapeutic target of gene therapy for 
gastric cancer using a dominant-negative form of HIF or HIF siRNA. 
Rac1, a major member of the Rho GTPase family, is related to tumorigenesis [153], 
invasion and metastasis [154], and angiogenesis [81, 155]. Xue et al. showed that VEGF and 
HIF-1α were down-regulated in gastric cancer cells which were transfected with a Rac1 siRNA 
expression vector [156]. Raf-1, an upstream molecule in the mitogen-activated protein kinase 
(MAPK) cascade, may also be involved in tumor angiogenesis [157]. The same group also 
showed similar results in gastric cancer cells with a Raf-1 siRNA expression vector [158].  
 
Other strategies 
Khare et al. delivered inducible nitric oxide (NO) synthase specifically to CEA-positive 
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gastric cancer cells [15]. NO directly induces autocytotoxicity and cytolysis of bystander cells. 
Synthesis of DNA at chromosome ends by telomerase may be necessary for indefinite 
proliferation of human cells [159]. Over the last decade, it has become clear that most human 
cancers activate telomerase at some point during tumorigenesis, while this activity is largely 
absent in most normal tissues [160]. Telomerase activity is also commonly positive in gastric 
cancer [56]. Inhibition of telomerase activity in MKN-45 gastric cancer cells by antisense human 
telomerase stable transfection induces apoptosis and growth arrest [161]. Ye et al. also reported 
growth inhibition effects of human telomerase antisense oligodeoxyribonucleotides in poorly 
differentiated MKN45 and moderately differentiated SGC-7901 gastric cancer cells, but not in 
well differentiated MKN-28 gastric cancer cells [162]. 
Heat shock proteins (HSPs), molecular chaperones, are induced by various stresses [163]. 
HSP70 is involved in the folding of nascent polypeptide chains and translocation of precursor 
proteins across the membranes of organelles [164]. HSP70 also interacts with mutated or altered 
oncogene and tumor suppressor gene products, which may be associated with development and 
progression of tumors [165, 166]. HSP70 is overexpressed in gastric cancer, as well as in other 
tumors [167]. Zhao et al. demonstrated that HSP70 antisense oligodeoxyribonucleotides inhibited 
cell growth and induced apoptosis in gastric cancer cells [168]. On the contrary, HSPs is an 
activator of the innate immune system [169, 170] and can carry antigens to antigen-presenting 
cells [171]. Taking these functions of HSPs into consideration, a selective delivery system 
targeted to cancer cells will be required for down-regulation strategy of HSP70 in vivo. 
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Combination of several strategies 
Cancer cells should be completely killed; otherwise, recurrence and/or metastasis will 
occur. Therefore, the synergistic effects of combining several approaches are promising. 
One attractive partner is chemotherapy. It was reported that the combination therapy of 
intratumoral administration of plasmid DNA encoding the bax gene complexed with a cationic 
lipopolyamine and the anti-cancer drugs 5-FU or CDDP significantly enhanced the anti-tumor 
effect in a gastric cancer model [172]. Takimoto et al. reported that histone deacetylase inhibitor 
such as sodium butylate could enhance the efficacy of an adenoviral vector carrying wild type 
p53 in gastric cancer cells by p53 activation and viral receptor up-regulation, in addition to its 
anti-tumor activity [173]. E2F-1, E2F family of transcription factor, has the ability to induce both 
cell cycle progression and apoptosis [174, 175]. Overexpression of E2F-1 by adenoviral gene 
transfer induced apoptosis in human gastric carcinoma cells, and this effect was enhanced by 
cyclin-dependent kinase inhibitors [176]. Namiki et al., demonstrated that NK4-expression by 
intraperitoneal injection of ternary complexes (plasmid DNA with cationic lipids and non-histone 
chromatin proteins) suppressed the gefitinib-resistance induced by the interaction between 
fibroblasts and scirrhous gastric cancer, and eventually, this tailor-made combination 
synergistically decelerated disease progression by inhibiting proliferative, angiogenic and 
anti-apoptotic effects in disseminated peritoneal tumor tissues [177]. Min et al. reported that the 
combination of dominant-negative insulin-like growth factor I receptor expression using an 
adenoviral vector and chemotherapy was very effective against gastric cancer xenografts in vivo 
[178]. Guo et al. constructed a combination of HSV-tk with a cytokine gene (IL-2 and 
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granulocyte macrophage colony-stimulating factor) and showed a strong anti-tumor effect in a 
gastric cancer model [179]. In addition, several groups overcame drug resistance by gene delivery. 
Zhang et al. reported that ZNRD1 (zinc ribbon domain-containing 1 protein) antisense nucleic 
acid transfection sensitized drug-resistant gastric cancer cells to vincristine, increased adriamycin 
accumulation and inhibited cell proliferation [180]. Guo et al. demonstrated that overexpression 
of the tumor suppressor Runx3 gene could sensitize gastric cancer cells to chemotherapeutic 
drugs by down-regulating not only bcl-2, but also MDR-1 and MRP-1 [181]. 
Virotherapy using conditionally replicative viruses is a newly developed therapeutic 
option for cancer [182, 183]. This approach is easily combined with gene therapy by genetic 
modification of the same viruses. Zhang et al. developed a combination of oncolysis with 
virotherapy targeted to telomerase-positive cancers, and anti-angiogenesis by gene therapy using 
an endostatin gene [149].  
Combination of gene therapy with radiation has also great potential to treat several 
cancers [184] including gastric cancer [178]. 
 
APPROACHES TO TREAT GASTRIC ULCER 
A gastric ulcer is a deep necrotic lesion penetrating through the entire mucosal thickness, 
the muscularis mucosae, and often involves the muscularis propria [185]. Ulcer healing, a 
genetically programmed repair process, includes inflammation, cell proliferation, 
re-epithelialization, formation of granulation tissue, angiogenesis, interactions between various 
cells and the matrix and tissue remodeling, all resulting in scar formation [186]. Because VEGF 
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and angiopoietin-1 are involved in angiogenesis, Jones et al. studied whether local gene therapy 
with naked DNA encoding these genes into the ulcer base could accelerate ulcer healing through 
enhanced angiogenesis [187]. They successfully demonstrated accelerated gastric ulcer healing. 
Co-injection of both genes led to more complete structural restoration. The same group also 
demonstrated that gene therapy with a serum response factor accelerated experimental gastric 
ulcer healing and promoted re-epithelialization and muscle restoration [188]. Finally, local 
injection of plasmid DNA encoding the cationic host defense peptide cathelicidin promoted 




In this review, we summarized stomach- and cancer-targeted gene transfer methods and 
therapeutic strategies for gastric diseases, including cancer and ulcer. Since gene expression in 
non-target tissues/cells can cause side effects, selective gene delivery systems targeted to the 
stomach and/or cancer cells must be developed. The route of vector transfer is an important issue 
which can determine efficacy and safety.  
H. pylori activate NF-κB via MAPK cascades, as a consequence IL-8 release from AGS 
gastric cancer cells [190] and macrophages [191] occur. IL-8 is a chemoattractant, which 
stimulate significant infiltration of neutrophils into gastric mucosa, leading to chronic gastritis. 
IL-8 is also a mediator of angiogenesis [192]. H. pylori increased expression of mRNAs encoding 
not only IL-8, but also VEGF, angiogenin, urokinase-type plasminogen activator, and 
metalloproteinase-9 by gastric carcinoma cells, suggested that H. pylori infection might regulate 
angiogenesis and invasion of human gastric carcinoma [193]. As future prospects, suppression of 
these genes by antisense or siRNA may inhibit tumor progression and angiogenesis caused by H. 
pylori infection. 
Tumor-associated macrophages (TAMs) have been shown to be symbiotically related to 
tumor cells; tumor cells recruit TAMs and provide them with survival factors, and in turn TAMs 
produce a variety of angiogenic factors in response to the tumor microenvironment [194]. 
Ishigami et al. reported that the degree of infiltration of TAMs positively correlated with depth of 
invasion, nodal status and clinical stage in gastric cancer patients [195]. Therefore, TAMs may be 
a potent target of gene therapy for gastric cancer as well as other cancer. As to targeted delivery to 
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macrophages, Kawakami et al. developed mannosylated cationic liposome/plasmid DNA 
complex and they successfully delivered foreign gene to macrophages in mice [196]. As well, a 
dominant negative monocyte chemoattractant-1 mutant (7ND) treatment inhibited TAMs 
recruitment and partially reduced angiogenesis and growth of melanoma [197], thus, this might 
also be effective for gastric cancer. 
As for gastric cancer, investigations were performed mainly in vitro gastric cancer cell 
lines. Some investigations showed in vivo therapeutic effects in s.c. tumor xenografts of gastric 
cancer cells; however, there are strong doubts about their efficacy in primary gastric cancer. In 
contrast, gene therapy for peritoneal dissemination of gastric cancer is promising since good 
results were reported in an animal model similar to the in vivo situation. Prophylactic usage of 
gene therapy after surgical resection may improve patient prognosis. For this purpose, an oral 
gene delivery system or controlled release formula of gene medicine should be developed. 
-26- 
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Table 1. Advantages and disadvantages of vector transfer routes for the stomach 






Effective gene transfer 
High selectivity 
Physical force against organ 
Limited region 
Limited frequent dosing 
Intraperitoneal Effective gene transfer Low selectivity 
Serosal surface 
Effective gene transfer 
High selectivity 
Necessity of laparoscopy 
Oral 
Easily administration 
Frequent dosing (daily intake) 




Table 2. Summary of strategies for gastric cancer treatment 
Categories Genes (with drugs) Vectors In vitro/in vivo References 
Suicide gene therapy     
 HSVtk (GCV) Adv In vitro [18] 
 HSVtk (GCV) Adv Intratumoral [19] 
 CD (5-FC) Adv i.p. [20] 
Growth inhibition and 
apoptosis induction 
    
 p53 CL In vitro [59] 
 p53 Adv Intratumoral [60] 
 p53 (HDAC inhibitor) Adv Intratumoral [173] 
 p51A Adv In vitro [66] 
 Bax Adv Intratumoral, i.p. [70] 
 Bcl-2 antisense (CDDP, 
PTX) 
Naked i.p. [77] 
 Bcl-XL siRNA CL In vitro [78] 
 RhoA siRNA or  
DN RhoA 
CL In vitro [86] 
 RhoA and RhoC siRNA Adv In vitro [87] 
 FasL Adv Intratumoral [89] 
 Pro-caspase-8 Adv i.p. [93] 
 Rev-caspase-3 CL In vitro [95] 
 Smad7 CL In vitro [107] 
 PTEN Adv Intratumoral [113] 
 Fhit Adv, AAV Oral [116, 117] 
 Puma Adv In vitro [118] 
 survivin antisense or 
DN survivin 
CL  Ex vivo [122] 
 E2F-1 (cyclin-dependent 
kinase inhibitor) 
Adv In vitro [176] 
Immunotherapy     
 IL-2 Retrovirus Ex vivo [125] 
 IL-10 Adv i.p. [126] 
 MG7-Ag mimotope Adv Subcutaneous [133] 
 ICAM-1 CL Ex vivo [136, 137] 
 ICAM-2 Adv Intratumoral [139] 
Anti-angiogenesis     
 sFlt-1 Adv i.p. [39] 
 NK4 Adv Intratumoral [145] 
 NK4 Adv i.p. [40] 
 Endostatin Adv Intratumoral [149] 
 DN HIF-1α Stable line Ex vivo [152] 
 Rac1 siRNA CL In vitro [156] 
-51- 
Abbreviations. Adv: Adenoviral vector; AAV: Adeno-associated viral vector; CL: Cationic liposomes; i.p.: 
intraperitoneal injection; CDDP: cisplatin; PTX: paclitaxel; DN: dominant-negative; iNOS: inducible nitric 
oxide synthase. 
 Raf-1 siRNA CL In vitro [158] 
Other strategies     
 iNOS Retrovirus In vitro [15] 
 Teromelase antisense CL In vitro [161] 
 HSP70 antisense Naked In vitro [168] 
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Figure legends 
Fig. (1). Section of the gastric wall and scheme of vector transfer routes. 
 
Fig. (2). Pathways for apoptosis induction and inhibition. 
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Fig. (1). 
 
 
 
-54- 
Fig. (2). 
 
 
